Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its blockbuster weight loss drugs Wegovy and Ozempic.

As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

The Danish pharmaceutical giant announced Friday that, amidst a recent downturn in the company’s stock, Lars Fruergaard Jørgensen would soon be stepping down as its top executive and the board ...

The company behind popular new drug Ozempic says its CEO, Lars Fruergaard Jorgensen, will step down following a plunge in the company's share price. Danish pharmaceutical giant Novo Nordisk's ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—heads for the exit. Under a mutual ...

As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition ...